AbbVie will invest $195 million in its North Chicago, IL manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. With construction planned to begin this fall, the expansion is part of AbbVie’s previously announced commitment to invest more than $10 billion of capital in the U.S.
The new North Chicago API facility will expand AbbVie’s chemical synthesis capabilities in the U.S., supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines. The facility will expand AbbVie’s existing U.S. manufacturing footprint, which supports more than 6,000 jobs across 11 manufacturing sites.
“Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs,” said Robert A. Michael, chairman and CEO. “This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.”
The post AbbVie Sets $195M Expansion of North Chicago Manufacturing Plant appeared first on Connect CRE.
